GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $3.81 Consensus PT from Brokerages

by · The Markets Daily

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) have received a consensus rating of “Hold” from the fifteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $3.8125.

Several equities research analysts have recently commented on the stock. TD Cowen raised their target price on shares of GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $3.50 target price on shares of GoodRx in a research note on Friday, May 8th. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, July 8th. Finally, Citigroup increased their price target on shares of GoodRx from $3.50 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th.

Read Our Latest Report on GoodRx

GoodRx Price Performance

Shares of GoodRx stock opened at $2.93 on Monday. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. The company has a market cap of $1.00 billion, a PE ratio of 48.84, a P/E/G ratio of 1.40 and a beta of 1.60. The business has a 50 day moving average of $2.81 and a 200 day moving average of $2.51. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. The company had revenue of $194.01 million during the quarter, compared to analyst estimates of $185.40 million. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The firm’s revenue was down 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 earnings per share. As a group, equities research analysts forecast that GoodRx will post 0.17 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in GDRX. Essential Partners LLC lifted its stake in shares of GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after purchasing an additional 11,295 shares during the period. Meridian Wealth Management LLC purchased a new stake in GoodRx in the fourth quarter worth $29,000. SG Americas Securities LLC purchased a new stake in GoodRx in the first quarter worth $29,000. Krilogy Financial LLC bought a new position in GoodRx in the first quarter worth $33,000. Finally, Quarry LP bought a new position in GoodRx in the third quarter worth $33,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

Featured Stories